ulcerative colitis semaglutide and Colitis: Safety Guide Semaglutide-Associated Ischemic Colitis in a

GLP-1 medicationsmore commonly known by their brand names such as Ozempic and Wegovy have the potential to reshape the eating and shopping habits of users

Research published in cardiovascular journals indicates these effects persist across different patient populations, including those with prediabetes, type 2 diabetes, and obesity without diabetes

Your provider may monitor closely but rarely needs to pause GLP-1 treatment unless infection is severe or recurrent

For instance, one study found that weekly treatment with semaglutide reduced risk of a combination of stroke, heart attack, and death from cardiovascular causes by 20% compared to a placebo